May 31, 2022
This keeps getting better
Not like we needed more reasons to anticipate ADA here’s another;
“Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle Libre 3 system for use by people four years and older6 living with diabetes.”
It’s ironic that this approval comes at the same time Dexcom states they are not hooking up with Insulet. It’s also ironic that the Libre3 is approved before the G7 yet there is no mention in the Abbott press release that the Libre3 received the iCGM designation. Nor is there any mention of . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.